Psoriasis

Dermatology Times' editor in chief highlights essential late-breaker data from AAD 2026, including upadacitinib, rezpegaldesleukin, icotrokinra, zasocitinib, envudeucitinib, sonelokimab, and more.

Investigators reported that individualized adalimumab dose adjustments based on serum drug levels could increase clinical response rates compared with standard dosing.

Dutch registry data show obesity and smoking predict higher psoriatic arthritis activity, making weight loss and quitting key to better control.

The analysis highlights potential disease-specific effects of GLP-1 pathway modulation across inflammatory conditions.

In this episode, Liza O'Dowd, MD, discusses the 52-week data from the ICONIC clinical program of icotrokinra, the most recently approved oral peptide agent for psoriasis.

New research shows podiatry students struggle to spot psoriasis and eczema on darker skin, exposing dermatology training gaps and driving calls for inclusive teaching.

Interim phase 2a data show ORKA-001, a half-life extended IL-23 inhibitor, achieved complete skin clearance in 63.5% of patients at week 16.

Although dermatologists are not expected to routinely prescribe GLP-1 drugs, they are increasingly encountering cutaneous effects, especially hair loss and facial volume loss.

Patients who are needle-averse may soon have effective non-injectable options with biologic-like results.

A new review examined the bone–vascular axis in psoriasis and how the current therapeutic toolbox can influence cardiovascular and skeletal health.

Liza O'Dowd, MD, discusses the drug's long road to FDA approval and what its oral delivery means for patients with plaque psoriasis.

Liza O'Dowd, MD, shared insights on the latest data on icotrokinra at the AAD Annual Meeting.

LEO Pharma shared 2 posters with data from the ongoing EFFISAYIL ON program, supporting long-term use of spesolimab for generalized pustular psoriasis.

Phase 3 data presented at AAD 2026 show once-daily oral therapy clears skin as early as week 4, offering a fast-acting option for patients.

Late-breaking data shared at AAD 2026 supports oral TYK2 envudeucitinib's efficacy and safety in moderate-to-severe plaque psoriasis.

IL-17 inhibitors are highly effective, but many patients still require switching due to treatment failure, loss of response, or intolerance.

Molecular NOS2/CCL27 testing outperforms standard biopsy reads for psoriasis versus eczema, reducing diagnostic uncertainty in CHE and speeding targeted treatment.

Omar Noor, MD, FAAD, discusses strategies to improve psoriasis care for patients facing adherence challenges related to lifestyle or cognitive barriers.

Clinical trial data showed approximately 70% of patients achieved clear or almost clear skin with icotrokinra by week 16.

Chovatiya discusses treat-to-target goals, biologics, BSA remission, and patient burden in psoriasis.

Results show that bimekizumab achieved significantly higher ACR50 response rates at week 16 than risankizumab in adults with active PsA.

Douglas DiRuggiero, DMSc, MHS, PA-C, emphasized that relying solely on body surface area underestimates psoriasis burden, particularly for patients with disease in high-impact or special areas.

Patients treated with deucravacitinib achieved higher ACR20 response rates at week 16 than those receiving placebo in the POETYK PsA studies.

Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series.

Nicholas Brownstone, MD, and other experts spotlighted cytokine hubs at the 2026 Winter Clinical Miami conference, linking chronic spontaneous urticaria and psoriasis/psoriatic arthritis to smarter targeted treatment choices.